Apart from Gilead’s (GILD) HIV and liver disease portfolios, the company’s product portfolio also includes drugs for treatment areas like oncology, cardiovascular, inflammation, and respiratory. The company’s other products segment reported revenues of $525 million for 2Q16 as compared to $495 million for 2Q15.
The oncology portfolio includes the drug Zydelig, which is used in combination with rituximab for the treatment of chronic lymphocytic leukemia (or CLL). It’s also used in the treatment of relapsed follicular B-cell non-Hodgkin lymphoma and small lymphocytic lymphoma. Zydelig reported revenues of $41 million in 2Q16.
The cardiovascular portfolio comprises of three drugs. Letairis is used in the treatment of pulmonary arterial hypertension. Lexiscan injection is used as a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging. Raneca is used for the treatment of patients with chronic angina.
During 2Q16, Letairis and Raneca reported revenues of $203 million and $153 million, respectively.
Inflammation and respiratory portfolio
The inflammation and respiratory portfolio include two drugs, Cayston and Tamiflu. Cayston is used for improving the respiratory symptoms in patients with cystic fibrosis and pseudomonas aeruginosa. Tamiflu is an influenza neuraminidase inhibitor used in the treatment of patients with influenza infection.
AmBisome and Macugen are other drugs from Gilead. AmBisome reported a decline in revenues to $87 million during 2Q16 as compared to $103 million during 2Q15. AmBisome is used in empirical therapy where fungal infections are presumed in febrile and neutropenic patients.
Investors can consider ETFs like the PowerShares Dynamic Biotechnology and Genome Portfolio ETF (PBE), which holds ~4.7% of its total assets in Gilead Sciences, in order to divest the risk.